Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone sodium phosphate
Drug ID BADD_D01833
Description Prednisolone phosphate is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]
Indications and Usage For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
Marketing Status Prescription; Discontinued
ATC Code A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB14631
KEGG ID D00981
MeSH ID C009022
PubChem ID 441409
TTD Drug ID Not Available
NDC Product Code 50383-040; 52128-164; 42799-812; 65089-0007; 66993-844; 62135-330; 59212-700; 71052-610; 42799-813; 50090-1582; 10695-109; 64958-0042; 0121-0759; 59212-702; 24002-0007; 81646-118; 63187-215; 22552-0051; 66993-846; 24208-715; 0121-0777; 67296-1505; 66993-845; 44523-182; 38779-0153; 65162-667; 50090-0955; 59212-701; 62991-1205; 0121-0773; 68788-7708; 49452-5995; 68791-104; 70166-549; 13925-166; 22552-0004; 17856-0759; 0121-0902; 49452-5996; 60432-212; 51927-0050
Synonyms prednisolone phosphate | Predsol | prednisolone sodium phosphate | prednisolone phosphate, sodium salt, (11beta)-isomer | prednisolone 21-phosphate sodium | prednisolone phosphate sodium | prednisolone phosphate, monosodium salt, (11beta)-isomer | prednisolone-21-phosphate | Pediapred
Chemical Information
Molecular Formula C21H27Na2O8P
CAS Registry Number 125-02-0
SMILES CC12CC(C3C(C1CCC2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=CC34C)O.[Na+].[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug withdrawal syndrome19.07.02.011; 08.06.02.004--Not Available
Dyspepsia07.01.02.001--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Electroencephalogram abnormal13.07.03.001--Not Available
Embolism venous24.01.01.003--Not Available
Epilepsy17.12.03.002--Not Available
Erythema23.03.06.001--Not Available
Euphoric mood19.04.02.006--
Exophthalmos06.09.04.001; 05.02.02.002--Not Available
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eyelid oedema06.04.04.004; 23.04.01.003; 10.01.05.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Glaucoma06.03.01.002--
Glucose tolerance impaired14.06.02.001; 05.06.02.001--
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haemoglobin13.01.05.018--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Hirsutism23.02.04.001; 05.05.01.005--
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypernatraemia14.05.04.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertriglyceridaemia14.08.02.001--
Hypertrophic cardiomyopathy03.07.02.004; 02.04.01.002--Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages